Results
A total of 3,193 separate articles were identified by the searches; 28 were selected for closer review and 10 articles were included in the final review, 1 retrospective case-control study, 7 retrospective cohort studies, and 2 prospective cohort studies, all from January 2003 to September 2015. Pooled data resulted in 2,966 patients with 553 traumatic intracranial hemorrhages (19%) in the combined antiplatelet group and 18,281 total patients with 1,422 (8%) traumatic intracranial hemorrhages in the combined control group. Analysis of pooled data resulted in an OR for traumatic intracranial hemorrhage of 1.87 (95% CI 1.27 to 2.74), indicating that antiplatelet therapy is an independent risk factor for traumatic intracranial hemorrhage in patients with traumatic brain injury. These results were confirmed in a sensitivity analysis after exclusion of studies with a high risk of bias. Risk of bias, primarily selection bias, was found to be high within the data set, although the authors found no evidence of publication bias when using a funnel plot. These results were similar when the authors examined only the patients with mild traumatic brain injury, with 
Commentary
Despite significant heterogeneity, the authors identified antiplatelet therapy to be a modest independent risk factor for intracranial bleeding after traumatic brain injury, increasing the risk of bleeding approximately two-fold. This finding was more robust for the mild traumatic brain injury group. Because all studies were ED based, the results are directly applicable, and the outcome of traumatic intracranial hemorrhage is clinically important; however, the rate of neurosurgical intervention was not reported in this analysis.
The majority of the patients included in this meta-analysis were receiving clopidogrel; therefore, it is reasonable to consider that preinjury use of clopidogrel confers an increased risk of traumatic intracranial hemorrhage similar to that of warfarin. There were not enough data to quantify the risk associated with aspirin monotherapy or other antiplatelet drugs.
The question of management of traumatic intracranial hemorrhage in patients receiving antiplatelet therapy is not addressed in this review, particularly the use of platelet transfusion. The evidence for platelet transfusion in traumatic intracranial hemorrhage in patients receiving antiplatelet therapy is based on observational studies with no evidence of benefit. 1 
